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PRS3
ACUTE EXACERBATION OF CHRONIC BRONCHITIS (AECB)
TREATMENT EFFECTIVENESS: COMPARISON OF
MACROLIDES TO FLUOROQUINOLONES
Wu EQ1, Birnbaum H1, Cifaldi M2, Kang YJ1, Colice GL3
1Analysis Group, Inc, Boston, MA, USA; 2Abbott Laboratories,
Abbott Park, IL, USA; 3Washington Hospital Center, Washington, DC,
USA
OBJECTIVES: The purpose of this study is to compare the 
effectiveness of ﬂuoroquinolones versus macrolides in treating
AECB. METHODS: The study sample was identiﬁed from a
large employer claims database covering the period 1999–2002.
Patients age 18–65 years with at least one diagnosis of AECB
were included in the study sample. The sample was further
restricted to AECB patients who had 13 months pre-index date
continuous eligibility. The index date was deﬁned as the date of
the ﬁrst prescription of either a macrolide or a ﬂuoroquinolone
during the period between 14 days before an AECB diagnosis
and 30 days following the diagnosis. The effectiveness, measured
by treatment failure rate, of ﬂuoroquinolones and macrolides,
were compared using multivariate logistic regression adjusting
for gender age, season of the year, additional oxygen therapy,
and patient COPD severity as measured by a severity score
developed by Wu, et al. Treatment failure rate was deﬁned as
occurrence of hospitalization, ER visit, switching of antibiotics,
ﬁlling of a second prescription of antibiotic, or use of oral cor-
ticosteroids within one-month following the index date, and was
compared using odds ratio (OR). Patients were categorized into
severe COPD (top 25% of severity distribution) and non-severe
(moderate/mild) COPD patients. RESULTS: When treated with
macrolides, severe COPD patients had signiﬁcantly lower failure
rates compared with patients on ﬂuoroquinolones (OR = 2.01,
p = 0.03). There are no differences in failure rate between
macrolides and ﬂuoroquinolones in treating moderate and mild
COPD patients. CONCLUSIONS: Macrolides are more effective
ﬁrst line therapies compared to ﬂuoroquinolones when treating
ﬂare-ups of severe COPD patients.
PRS4
ESTIMATING THE NUMBER OF CASES OF DIAGNOSED
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD):
USE OF MEDICAL CLAIMS DATA VERSUS ALTERNATIVE
METHODOLOGIES
Miller JD1, Boulanger L1, Russell MW1, Marton J2, Menzin J1
1Boston Health Economics, Inc, Waltham, MA, USA; 2Pﬁzer Inc, New
York, NY, USA
OBJECTIVES: To estimate the prevalence and annual incidence
of diagnosed COPD from medical claims data and to compare
results with those derived through alternative methodologies.
METHODS: Claims data were acquired from a US managed 
care organization database with records for approximately ten
million members in 20 states. The COPD cohort comprised
patients aged 25+ years with one or more medical claims with a
COPD diagnosis in 2002. For prevalence, patients were required
to be eligible for coverage during 2002, while patients in the inci-
dence estimation were required to be eligible for medical cover-
age in both 2001 and 2002 but without any COPD diagnoses 
in 2001. Claims-based estimates of prevalence and incidence
(overall and by age group) were compared to corresponding pub-
lished data from other sources. RESULTS: We identiﬁed 64,141
patients with a diagnosis of COPD (an overall prevalence of
3.7%). Prevalence progressively increased from 0.3% in patients
aged 25–34 years to 11.8% in patients aged 75+ years. These
estimates are generally lower than other sources. For example,
National Health Interview Survey estimates, based on respon-
dent self-reported COPD or recall of being told they have the
disease, ranged from 3.9% to 10.6% in the youngest and oldest
age groups, and were about 6.0% overall. A total of 7347 newly-
diagnosed COPD patients were found, generating an annual inci-
dence rate of 0.95%. Rates increased from 0.08% in patients
aged 25–34 years to 2.07% in patients aged 75+ years, some-
what higher than estimates from European studies that used
general practitioner case registrations as a data source. No com-
parable U.S. studies could be identiﬁed. CONCLUSION: Dis-
parities exist in epidemiological estimates of COPD depending
on data, patient populations, and methodologies employed.
Further studies are needed to clarify the most valid and reliable
data and methods for studying the epidemiology of diagnosed
COPD.
PRS5
EVALUATION OF THE ASSOCIATION BETWEEN SEVERITY OF
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
WITH HEALTH-RELATED UTILITY (EQ5DINDEX) AND
HEALTH CARE RESOURCE USE
Currie CJ1, Grifﬁths T1, Gosden T2, Morrissey M1, Patel TC3,
McEwan P1
1Cardiff University, Cardiff, UK; 2Pﬁzer Limited, Surry, UK;
3University Hospital of Wales, Cardiff, UK
OBJECTIVE: COPD is a progressive and debilitating disease.
The purpose of this study was to directly characterize utility and
hospital resource use in people with COPD. METHODS: Data
were abstracted from the Health Outcomes Data Repository
(HODaR) describing the treatment patterns and outcomes of
299 subjects with COPD with corresponding lung function 
measurements. Patients were classiﬁed according to the GOLD
classiﬁcation based on their actual to predicted FEV1values. Pre-
dicted FEV1values were estimated from a subjects’ height, age
and sex. These patients were hospital treated subjects. Total
mean number of visits to/from a GP and practice nurse were cal-
culated in the six weeks prior to the survey, along with a measure
of utility (EQ5Dindex). RESULTS: Of the 299 subjects, there were
11 (3.7%), 74 (24.7%), 140 (46.8%) and 74 (24.7%) in GOLD
classes I to IV, respectively. There was an inverse association
between the GOLD classiﬁcation and mean EQ5Dindex: 0.52
(0.27), 0.44 (0.34), 0.42 (0.33) and 0.39 (0.31), for GOLD
classes I to IV, respectively. Regarding resource use, in the year
prior to their most recent FEV1 measurement was on average 2.1,
2.3, 2.4 and 2.1 hospital admissions for GOLD I to IV, respec-
tively. Additionally, the mean length of stay in the previous year
was 11.6, 16.6, 17.7 and 17.3 days, correspondingly. Mean (SD)
primary care visits increased from 2.9 (2.5) per person for
GOLD-I to 4.6 (7.4) for GOLD-IV, respectively. CONCLU-
SIONS: The EQ5Dindex estimates showed clearly that this disease
results in very poor quality of life, and that this is inversely asso-
ciated with disease severity. COPD was also extremely resource
intensive in all stages of disease severity. The changes in the lungs
of patients with COPD are irreversible; however, active chronic
disease management strategies may impact on the ﬁnancial and
humanistic cost of this disease.
PRS6
COMPARISON OF RESOURCE USE AND DIRECT COSTS OF
CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH AND
WITHOUT COMORBID DEPRESSION IN 2001
Viswanathan H,Thomas III J
Purdue University, West Lafayette, IN, USA
OBJECTIVES: The objectives of this study were to determine
and compare resource utilization and direct costs for adults diag-
nosed with chronic obstructive pulmonary disease with and
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without comorbid depression in the US in 2001. METHODS:
Retrospective case-control analysis was conducted of the 2001
Medical Expenditure Panel Survey. In 2001, 32,122 persons
from the US civilian noninstitutionalized population were sur-
veyed. A total of 1101 patients 18 years or older with chronic
obstructive pulmonary disease were identiﬁed. Cases and con-
trols were identiﬁed using ICD-9 codes. The data contained 153
cases with chronic obstructive pulmonary disease and depression
and 948 similar patients without comorbid depression. Cases
were matched at a 1 :1 ratio to controls based on age, race,
gender, and number of comorbidities apart from depression. 
The matching procedure resulted in 145 pairs. Sample estimates
were projected to the population. Expenditure variables repre-
sent sums of all annual out-of-pocket expenditures and third
party payments. Differences in resource use and expenditures
between cases and controls were examined using t-tests. Data
were analyzed using SAS Version 8.2. RESULTS: Patients with
chronic obstructive pulmonary disease and comorbid depression
had higher average total health care expenditures ($10,845 vs.
$6,430; p = 0.0231), expenditures for prescription medications
($2,643 vs. $1574; p = 0.0007), use of ofﬁce-based visits (15.5
vs. 9.4; p = 0.0027), and number of annual prescription med-
ications purchased (45.8 vs. 27.9; p = 0.0001) than the control
group. Net incremental expenditures associated with comorbid
depression were $7,030,575,677 for total health care and
$1,698,632,604 for prescription medications. CONCLUSIONS:
Total health care expenditures were 1.7 times higher for patients
with chronic obstructive pulmonary disease and comorbid
depression than for similar patients without depression matched
on age, gender, race, and number of comorbidities. Depression
in conjunction with chronic obstructive pulmonary is associated
with considerable health care expenditures and utilization of
ofﬁce-based services and prescription medications.
PRS7
PHARMACOECONOMIC ANALYSIS OF TIOTROPIUM THERAPY
IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY
DISEASES IN HONG KONG ¡V A PRELIMINARY REPORT
Lee KK, Lee VW, Hui DS
The Chinese University of Hong Kong, Hong Kong, China
OBJECTIVES: The prevalence of chronic obstructive pulmonary
disease (COPD) in Hong Kong has been estimated to be 0.35 per
1000 population. The cost of management can therefore trans-
late into an enormous burden on the health care budget. Current
pharmacotherapy includes bronchodilators plus anticholinergics.
Patient compliance can be a problem due to multiple daily
dosing, hence the present study aims to evaluate the potential
beneﬁts of tiotropium with once-daily dosage. METHODS: The
cost of management of COPD was estimated by retrospective
review of the history of a cohort of COPD patients admitted to
the Prince of Wales Hospital (PWH) in Hong Kong from January
1, 2001 to December 31, 2001. Cost items included hospital-
ization, procedures, laboratory tests, medications and outpatient
clinic visits. The cost-effectiveness (CE) model for COPD devel-
oped by Boehringer-Ingelheim was used to assess the CE of
COPD therapies. All analysis was based on local cost data, and
probabilities of events and efﬁcacy data of tiotropium were
adopted from overseas published randomized controlled trials as
there is yet no local published data. The study was performed
from the perspective of a public hospital. RESULTS: Data of 30
patients admitted to the PWH due to COPD were analyzed with
the model. Compared to ipratropium, the once-daily dosage of
tiotropium showed a decrease in number of exacerbations (0.89
vs. 1.21), a decrease in the management cost due to exacerba-
tions (US$2550 vs. 4183) and the cost per exacerbation avoided
due to tiotropium was US$4278. CONCLUSION: Based on 
our preliminary results, tiotropium appears to be a more cost-
effective agent in the treatment of COPD when compared to
ipratropium.
PRS8
COST-EFFECTIVENESS ANALYSIS OF TIOTROPIUM FOR
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
PATIENTS IN JAPAN
Nishimura S1, Kobayashi M2, Hasegawa T3
1Kyoto University, Kyoto, Kyoto, Japan; 2Crecon Research and
Consulting Inc, Shibuya,Tokyo, Japan; 3Pﬁzer Japan Inc,Yoyogi,
Shibuya-ku, Japan
OBJECTIVE: Chronic obstructive pulmonary disease (COPD) is
a major cause of death and disability throughout the world. The
objective of this study was to evaluate the health/economics 
consequence of four treatments (tiotropium, ipratropium, sal-
meterol and usual care) for patients with COPD in Japan.
METHODS: In order to estimate the patient’s prognosis for one
year, we constructed a Markov model based on the model devel-
oped by Oosenbrink J et al. in Netherlands. Three Markov stages
were set based on the degree of patient’s symptoms, e.g., mod-
erate, severe, and very severe. Acute exacerbation was also
included in the model. Transition probabilities were derived from
several clinical trials. The duration of remaining in the moder-
ate stage was used to deﬁne effectiveness. This study was con-
ducted from the payer’s perspective and only direct medical costs 
were considered. Since the time horizon was one year, discount-
ing was not considered. RESULTS: The expected costs for
tiotropium, ipratropium, salmeterol and usual care were
JPY559,314, JPY771,395, JPY612,707 and JPY621,400, respec-
tively ($1 = JPY103.84). The periods of duration of remaining
in the moderate stage (months) were 8.09, 5.56, 6.99 and 6.43,
respectively. The numbers of acute exacerbation were 0.80, 1.19,
0.96 and 0.91, respectively. A sensitivity analysis on the proba-
bility of home oxygen therapy during maintenance therapy also
showed that the tiotropium was the most cost-effective treat-
ment. CONCLUSION: In spite of the highest daily drug cost,
tiotropium is a cost-saving therapy for treatment of COPD
patients in Japan.
PRS9
ADHERENCE TO RESPIRATORY MEDICATIONS IN VA
PATIENTS WITH CHRONIC LUNG DISEASE
Lee TA1, Bartle B1, McLaughlin T2, Dirani R3
1Hines VA Hospital, Hines, IL, USA; 2NDC Health, Phoenix, AZ, USA;
3Pﬁzer Inc, New York, NY, USA
OBJECTIVES: Most adherence studies have focused on oral
medications, with less attention on diseases where non-oral
routes of administration are predominant. Our objective was to
estimate adherence in VA patients using medications for chronic
respiratory disease and examine factors related to adherence.
METHODS: We identiﬁed patients treated at Chicago-area VAs
that ﬁlled at least two respiratory medications between 08/2002
and 07/2003 (baseline period). We calculated medication pos-
session ratios (MPRs) for each class of respiratory medication
between 08/2003 and 07/2004 (study period) that patients ﬁlled
during the baseline period. Patients were classiﬁed as having
asthma, COPD, combined asthma and COPD (CAC) or none
based on diagnoses at baseline. Average MPR for each medica-
tion category was calculated and logistic regression was used to
identify factors associated with MPRs of >= 75%. RESULTS:
There were 7511 patients included (96.7% male, 35% white).
The number of patients by disease were: COPD = 3721 (49.5%);
asthma = 1045 (13.9%); CAC = 726 (9.7%) and none = 2019
